Pfizer Inc.
Rating
Updated: Aug 12, 2026Why Price Moved
The stock declined as headlines suggested better d...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehe...
Latest News
22 hours ago · fool.com
Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead.
2 days ago · fool.com
Is Pfizer an Excellent Dividend Stock to Buy?Pfizer (PFE +0.07%) has experienced unprecedented circumstances in the previous decade.
2 days ago · fool.com
3 Dividend Stocks to Buy and Hold for 10 YearsThey have a knack for increasing their dividends even when facing challenges.
3 days ago · 247wallst.com
Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
4 days ago · fool.com
Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.
6 days ago · zacks.com
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
7 days ago · seekingalpha.com
Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptPfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
7 days ago · marketbeat.com
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center StagePfizer NYSE: PFE Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products.
7 days ago · zacks.com
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
7 days ago · 247wallst.com
Pfizer's 6% Yield Masks a Fragile Dividend StoryPfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PFE